Supplemental Figures S1-S42 from The Pan-Tumor Landscape of Gene Amplifications and Copy Number Amplification Ratio for Established and Emerging Clinical Targets

作者：Jessica Lee, Júlia C.F. Quintanilha, Kuei‐Ting Chen, Bernard Fendler, Candice Francheska B. Tambaoan, Ryon P. Graf, Nicole B. Odzer, Lajos Pusztai, Maryam B. Lustberg, Harshabad Singh, Matthew R. Strickland, Tess A. O’Meara, Sara M. Tolaney, Timothy A. Yap, Jeffrey S. Ross, Amaya Gascó Hernández, Brennan Decker, Richard S.P. Huang, Samuel J. Klempner, Ethan Sokol, Alexa B. Schrock · 年份：2026 · DOI：10.1158/1078-0432.32845473 · 研究领域：HER2/EGFR in Cancer Research、Radiomics and Machine Learning in Medical Imaging、Advanced Breast Cancer Therapies

<p>Supplemental Figure 1: Modeled CN vs. AmpRatio Supplemental Figure 2: Amplification ratio purity invariance Supplemental Figure 3: Modeled gene CN vs. AmpRatio Supplemental Figure 4: CONSORT diagram Supplemental Figure 5: Pan-tumor MDM2 amplification landscape Supplemental Figure 6: MDM2 co-alteration landscape Supplemental Figure 7: Tissue ploidy distribution by tumor type Supplemental Figure 8: CN segment length vs. AmpRatio Supplemental Figure 9: Amplicon focality Supplemental Figure 10: Pan-tumor AmpRatio distribution of emerging targets Supplemental Figure 11: Breast ERBB2 co-alteration landscape Supplemental Figure 12: GE ERBB2 co-alteration landscape Supplemental Figure 13: CRC ERBB2 co-alteration landscape Supplemental Figure 14: Breast CGDB CONSORT diagram Supplemental Figure 15: GE CGDB CONSORT diagram Supplemental Figure 16: CRC CGDB CONSORT diagram Supplemental Figure 17: rwPFS for ERBB2-amplified mBC, aGE, and mCRC patients treated with trastuzumab-based regimens Supplemental Figure 18: Exploratory AmpRatio cutoffs for ERBB2-amplified mBC, aGE, and mCRC patients treated with trastuzumab-based regimens Supplemental Figure 19: Outcomes for ERBB2-amplified mBC patients treated with T-DXd Supplemental Figure 20: Exploratory AmpRatio cutoffs for ERBB2-amplified mBC patients treated with T-DXd Supplemental Figure 21: Performance of ERBB2 AmpRatio for predicting HER2-positivity Supplemental Figure 22: Association between ERBB2 AmpRatio and HER2 IHC/FISH Supplem...